Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth

  • Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact

    • Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales

    • Cosentyx (USD 176 million) continues to grow strongly, benefitting from long-term efficacy data for psoriasis and new launches in AS and PsA[3]

    • Entresto (USD 17 million) launch continues to accelerate in EU, field force ramping up in US

  • Core[1] operating income declines (-5% cc), driven by generic …
/by

Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth

  • Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact

    • Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales

    • Cosentyx (USD 176 million) continues to grow strongly, benefitting from long-term efficacy data for psoriasis and new launches in AS and PsA[3]

    • Entresto (USD 17 million) launch continues to accelerate in EU, field force ramping up in US

  • Core[1] operating income declines (-5% cc), driven by generic …
/by